Candel Therapeutics Showcases Groundbreaking Phase 3 Trial Data
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel) (NASDAQ: CADL), a pioneering biopharmaceutical company dedicated to developing innovative biological immunotherapies for cancer treatment, has made headlines with its recent announcement regarding the presentation of Phase 3 data from its CAN-2409 study. This momentous event is scheduled to take place at the prestigious American Society for Radiation Oncology (ASTRO) Annual Meeting, a gathering of leaders in the field, running from late September to early October.
Details of the CAN-2409 Presentation
The highlight of this year's conference will undoubtedly be the oral presentation led by Glen Gejerman, MD, MBA, from Hackensack University Medical Center. The abstract, titled "Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409 + Prodrug Combined with Standard of Care External Beam Radiation for Newly Diagnosed Localized Prostate Cancer," aims to provide clinicians and researchers with compelling insights into this promising treatment.
Presentation Specifics
- Abstract Overview: Focuses on innovative approaches combining CAN-2409 with current standard therapies for localized prostate cancer.
- Session Title: SS 03 - GU 1: Advances in Localized Prostate Cancer.
- Date & Time: Set for Sunday, September 28, with a focused session from 2:30 PM to 2:40 PM PT.
- Venue: Room 24, Moscone Center, San Francisco.
Significance of the Research
This trial marks a pivotal step not only for Candel but also for patients facing the challenges of localized prostate cancer. As standard treatments continue to evolve, the integration of CAN-2409 into existing protocols could represent a leap forward in enhancing treatment efficacy and patient outcomes.
ASTRO Highlights Session
Moreover, the abstract's inclusion in the ASTRO Science Highlights - Genitourinary Cancer session underscores the significance of the findings. Attendees will gain insights into the latest breakthrough research in genitourinary oncology, scheduled for September 28 at 8:00 AM PT.
Candel Therapeutics: A Leader in Cancer Immunotherapy
Candel Therapeutics takes pride in its focus on creating off-the-shelf, viral immunotherapy products that can trigger personalized immune responses against tumors. The company has developed two leading clinical-stage platforms utilizing novel genetically modified viruses—adenovirus and herpes simplex virus (HSV). CAN-2409 stands out as a flagship candidate from the adenovirus platform.
Previous Trials and Regulatory Milestones
The company recently completed pivotal trials demonstrating CAN-2409's potential to meet vital endpoints in localized prostate cancer treatments. Elsewhere, exciting results were also documented in Phase 2a trials addressing non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
Thanks to its promising results, the FDA has recognized CAN-2409 by granting it the Regenerative Medicine Advanced Therapy Designation for newly diagnosed patients in the aforementioned cancer categories. Earlier, similar designations underscored Candel’s commitment to creating accessible and impactful treatment options in oncology.
Future Prospects for CAN-3110
Looking beyond CAN-2409, Candel’s lead candidate from the HSV platform, CAN-3110, is currently undergoing a promising phase 1b trial targeting recurrent high-grade glioma. Its initial findings have drawn positive attention from the medical community, further establishing Candel as a trailblazer in the search for effective cancer therapies.
Advancements in Viral Immunotherapy
Candel’s innovative enLIGHTEN™ Discovery Platform employs sophisticated analytics to augment its HSV-based therapies. By harnessing insights from human biology, the company aims to push the boundaries of what viral immunotherapies can achieve for patients battling solid tumors.
Investor Insights and Engagement
For investors looking to connect, Candel Therapeutics welcomes inquiries. The Vice President of Investor Relations and Business Development, Theodore Jenkins, is available for discussions. His contact information ensures that dialogues about the company's transformative growth and strategies remain open.
Frequently Asked Questions
What is CAN-2409?
CAN-2409 is Candel Therapeutics' lead product candidate designed to enhance immune responses in patients with localized prostate cancer.
When will the important presentation occur?
The oral presentation will take place on September 28 during the ASTRO meeting, focusing on phase 3 trial results.
Who is leading the presentation?
Dr. Glen Gejerman from Hackensack University Medical Center will present the findings.
What is the significance of the FDA designations?
FDA designations like Fast Track and Regenerative Medicine Advanced Therapy highlight the potential of CAN-2409 to provide significant benefits for patients.
How is Candel contributing to cancer treatment?
Candel is innovating in the area of viral immunotherapies that can elicit personalized immune responses, improving treatment outcomes for different cancer types.
